We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 24, 2020

First-in-Human Study of Taletrectinib in Patients With Advanced Solid Tumors

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
U.S. Phase I First-in-Human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients With Advanced Solid Tumors
Clin. Cancer Res 2020 Jun 26;[EPub Ahead of Print], KP Papadopoulos, E Borazanci, AT Shaw, R Katayama, Y Shimizu, VW Zhu, TY Sun, HA Wakelee, R Madison, AB Schrock, G Senaldi, N Nakao, H Hanzawa, M Tachibana, T Isoyama, K Nakamaru, C Deng, M Li, F Fan, Q Zhao, Y Gao, T Seto, PA Jänne, SI Ou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading